SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is being discussed alongside concerns about its heavy debt load, rising borrowing costs and whether AI demand and contract backlog can support its financing needs, with HSBCs bearish assessment adding to the pressure. Traders are split between viewing the balance-sheet risks and insider selling as reasons for further downside and arguing that strong demand, the backlog and Nvidia ties make the drop a buying opportunity.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is fueling a heavily bearish conversation, with traders tying its political-proxy appeal to concerns about Trumps approval and the midterms, while questioning the companys business traction. A smaller bullish contingent sees a possible trading bounce and points to the pending TAE fusion deal as a potential pivot.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to elevated crude prices and fears that Middle East shipping or energy-infrastructure attacks could disrupt supply, while weighing possible diplomacy and Russian supply relief. The community is split between bulls focused on geopolitical risk and bears expecting the risk premium to fade, with some also warning that contract-roll effects and an extended run may amplify volatility.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rally to a 52-week high is driving discussion, with traders citing momentum and rotation into defensive, dividend-paying pharma amid broader market weakness. Bulls see a potential breakout, while skeptics point to resistance and say a fresh company-specific catalyst is needed.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential but also to concerns about modest symptom improvement, agitation-related side effects, and discontinuations. Traders are divided, with some viewing the move as a fading bounce and adding shorts while others point to bullish analyst commentary.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly results beat expectations and the company raised its outlook, but shares fell as traders weighed rising costs, weaker cash flow and a loss in its insurance business. The reaction has split the community between buyers calling the selloff unjustified after a strong report and bears focused on the cost pressures and weak price action.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is in focus amid volatile swings tied to a tech and AI-led selloff followed by a relief rebound. Traders disagree over whether the bounce can hold or is a bull trap, while concerns about AI funding and hedge-fund selling, rising oil and inflation, and upcoming megacap earnings add to uncertainty.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings and revenue beat and a new multiyear buyback, as traders focus on the narrowed profit outlook with its midpoint unchanged and declining U.S. sales and market share. Some see the decline as a buying opportunity given cash generation and capital returns, while others argue the outlook failed to justify the valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are BZH, LNTH, BGMS Obtaining Fair Deals for their Shareholders?

Are BZH, LNTH, BGMS Obtaining Fair Deals for their Shareholders? Are BZH, LNTH, BGMS Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 29, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

ACT NOW - The M&A Class Action Firm Is Investigating the Merger -- FHB, INDV, ITGR, and LNTH

ACT NOW - The M&A Class Action Firm Is Investigating the Merger -- FHB, INDV, ITGR, and LNTH ACT NOW - The M&A Class Action Firm Is Investigating the Merger -- FHB, INDV, ITGR, and LNTHPR NewswireNEW YORK, Sept. 28, 2026 NEW YORK, Sept. 28, 2026 /PRNewswire/ --Class Action Attorney Juan Monteverde...

Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders?

Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders? Are LNTH, ITGR, CZR Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 11, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

LNTH Stock Alert: Halper Sadeh LLC is Investigating Whether Lantheus Holdings, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lantheus Holdings, Inc. (NASDAQ: LNTH) to Curium US Holdings LLC for $102.50 per share in cash, plus non-transferable Contingent Value Rights providing for up to $12.00 per share in potential additional cash payments...

Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?

Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 7, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading

Equity

Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert. 


$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH) PR Newswire NEW YORK, Aug. 3, 2026 NEW YORK, Aug. 3, 2026 /PRNewswire...

Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?

Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders? Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, Aug. 3, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders PR Newswire MILWAUKEE, Aug. 3, 2026 MILWAUKEE, Aug...

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the following geographical segments U.S. and International. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Moderna is seeking approval for mRNA-1010, its experimental mRNA-based seasonal flu vaccine for adults 50 and older.</li><li>Capricor is seeking full approval for Deramiocel, a cell therapy aimed at heart damage caused by Duchenne muscular dystrophy, after an earlier rejection.&nbsp;</li><li>Ultragenyx is seeking approval for DTX401, a one-time gene therapy for glycogen storage disease type Ia, a rare inherited metabolic disorder, by August 23.</li></ul><p>The U.S. Food and Drug Administration is set to rule on five closely watched treatments in August from Moderna, Lantheus Holdings, Bristol Myers Squibb, Capricor Therapeutics and Ultragenyx Pharmaceutical.</p><p>Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert as the outcomes could drive sharp near-term moves across the sector.</p><h2 class="st-heading-2">August 5: Moderna’s Flu Shot (<a href="https://stocktwits.com/symbol/MRNA">MRNA</a>)</h2><p>Moderna is seeking approval for mRNA-1010, its experimental mRNA-based seasonal flu vaccine for adults 50 and older. An FDA advisory panel already voted unanimously in favor of the shot in June, and the FDA is slated to decide on its application by August 5.</p><p>The FDA initially refused to file Moderna’s application in early February 2026, citing concerns that the comparator vaccine used in the main trial did not reflect the best available care for older adults. Moderna revised its plan, and now the company is seeking a traditional approval for adults aged 50-64 and an accelerated approval for adults 65 and older. If granted accelerated approval in the patient population, Moderna will be required to conduct another study to confirm effectiveness in the group.</p><h2 class="st-heading-2">August 13: Lantheus’ Alzheimer’s Scan (<a href="https://stocktwits.com/symbol/LNTH">LNTH</a>)</h2><p>Lantheus wants approval for MK-6240, a PET imaging agent that detects tau protein tangles in the brain, a hallmark of Alzheimer’s disease. Doctors would use the scan to help confirm the presence of tau pathology, stage the disease, and guide treatment decisions.</p><p>The FDA accepted the company’s application seeking approval in October and granted it a fast-track designation. The application is based on two late-stage trials in people with early Alzheimer’s disease. In both trials, the scan identified patients with tau pathology and ruled out people without it, to support the application. The FDA will decide on the application by August 13 at the latest.</p><h2 class="st-heading-2"><br>August 17: Bristol Myers Squibb’s Myeloma Drug (<a href="https://stocktwits.com/symbol/BMY">BMY</a>)</h2><p>Bristol Myers Squibb is seeking approval for iberdomide, an oral drug combined with existing medicines for patients whose multiple myeloma has returned or stopped responding, by August 17. It works by helping the immune system attack cancer cells more effectively while also directly killing myeloma cells.</p><p>Bristol Myers’ application was accepted by the FDA in February and granted priority review. The application relies on the large late-stage trial where iberdomide, together with Daratumumab and Dexamethasone, showed a statistically significant improvement in minimal residual disease (MRD) negativity rates compared to control arms. MRD negativity means no detectable cancer cells remain after treatment — an early sign of deep response.</p><h2 class="st-heading-2">August 22: Capricor’s Duchenne Therapy (<a href="https://stocktwits.com/symbol/CAPR">CAPR</a>)</h2><p>Capricor is seeking full approval for Deramiocel, a cell therapy aimed at heart damage caused by Duchenne muscular dystrophy. After an earlier rejection, the company submitted new data from its late-stage HOPE-3 trial to the FDA.</p><p>However, in July, an advisory committee voted 9–3 against the claim that the available evidence provides substantial proof of effectiveness for treating DMD cardiomyopathy. The vote is non-binding, meaning the FDA could still approve the therapy.</p><h2 class="st-heading-2">August 23: Ultragenyx’s Gene Therapy (<a href="https://stocktwits.com/symbol/RARE">RARE</a>)</h2><p>Ultragenyx is seeking approval for DTX401, a one-time gene therapy for glycogen storage disease type Ia, a rare inherited metabolic disorder, by August 23. People with GSDIa cannot release stored sugar from the liver, leading to dangerous drops in blood sugar (hypoglycemia) during fasting, excess glycogen buildup in the liver and kidneys, and other long-term complications. &nbsp;</p><p>The FDA granted priority review to Ultragenyx’s application in February. There are currently no approved treatments that address the underlying cause of GSDIa.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around MRNA trended in the ‘bearish’ territory at the time of writing, while sentiment around RARE and LNTH stayed at ‘neutral’ levels. Sentiment around CAPR and BMY was ‘extremely bullish’ at the time of writing.</p><p>While MRNA stock has gained 87% year-to-date, LNTH has added 52%, BMY 21%, and RARE 9%, while CAPR fell 85%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvax-stock-rises-ahead-of-q2-earnings-as-focus-shifts-to-licensing-deals/cZoTFaURJ3L">NVAX Stock Rises Ahead Of Q2 Earnings As Focus Shifts To Licensing Deals</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Photo by Sarah Silbiger/Getty Images)

Moderna is seeking approval for mRNA-1010, its experimental mRNA-based seasonal flu vaccine for adults 50 and older.Capricor is seeking full approval for Deramiocel, a cell therapy aimed at heart damage caused by Duchenne muscular dystrophy, after an earl

Bristol-Myers Squibb Co.

Capricor Therapeutics Inc

Moderna Inc

Ultragenyx Pharmaceutical Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$100.24
Prev Close	$99.92
Open	$99.85
Dividend Yield	0.00%
50-Day Moving Average	$100.35
Beta	0.45
Avg. Volume	1.04M
PE Ratio	24.15

52-Week High	$111.86
52-Week Low	$50.16
Market Capitalization	$6.52B
EPS (Annual)	$3.41
Price to Book	4.97
Revenue Per Employee	$1.29M

Feed

News

Sentiment

Earnings

Fundamentals

Info

LNTH Fundamentals